News

Wound-specific Bacteria May Be Targets for DEB Treatment

A distinct set of bacteria colonizes the skin in and around wounds in people with dystrophic epidermolysis bullosa (DEB), according to a new study. The finding suggests that these patients may benefit from therapies that specifically target those bacteria and that encourage the growth of non wound-associated bacteria instead.

Gentamicin Lessened Ocular Lesions in Junctional EB

Topical administration of the antibiotic gentamicin to the eye restored the production of a key skin health protein called laminin 332 while rapidly lessening eye lesions in a woman with junctional epidermolysis bullosa (JEB), a study reports. The study, “Topical gentamicin ointment induces LAMB3 nonsense mutation…

Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB, Fully Enrolled

Krystal Biotech announced the full enrollment of a pivotal Phase 3 clinical trial of its topical gene therapy B-VEC (beremagene geperpavec) as a skin wound treatment for people with dystrophic epidermolysis bullosa (DEB). Top-line results on the 31 patients in the randomized GEM-3 trial (NCT04491604), a mix of children…

Amryt Pharma Advances Regulatory Applications for Filsuvez

Amryt Pharma has completed its rolling submission of an application to the U.S. Food and Drug Administration seeking the approval of Filsuvez (Oleogel-S10), a topical gel to heal skin wounds in people with junctional (JEB) and dystrophic epidermolysis bullosa (DEB). The new drug application (NDA) includes a request for priority review, which can…